Enzon Pharmaceuticals (ENZN): Price and Financial Metrics

Enzon Pharmaceuticals (ENZN): $0.08

0.01 (+18.84%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add ENZN to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of 481

in industry

ENZN Price/Volume Stats

Current price $0.08 52-week high $0.27
Prev. close $0.07 52-week low $0.06
Day low $0.06 Volume 17,946
Day high $0.08 Avg. volume 12,698
50-day MA $0.09 Dividend yield N/A
200-day MA $0.14 Market Cap 5.76M

ENZN Stock Price Chart Interactive Chart >

ENZN Stock Summary

  • For ENZN, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
  • With a price/sales ratio of 256.9, ENZON PHARMACEUTICALS INC has a higher such ratio than 98.58% of stocks in our set.
  • ENZN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.77% of US stocks.
  • Stocks that are quantitatively similar to ENZN, based on their financial statements, market capitalization, and price volatility, are CIA, HRTG, BPOP, CHMG, and FUNC.
  • ENZN's SEC filings can be seen here. And to visit ENZON PHARMACEUTICALS INC's official web site, go to www.enzon.com.

ENZN Valuation Summary

  • In comparison to the median Healthcare stock, ENZN's price/sales ratio is 6219.05% higher, now standing at 265.4.
  • Over the past 243 months, ENZN's price/earnings ratio has gone down 44.2.

Below are key valuation metrics over time for ENZN.

Stock Date P/S P/B P/E EV/EBIT
ENZN 2023-12-29 265.4 2.7 -28.6 -42.7
ENZN 2023-12-27 261.5 2.7 -28.2 -42.8
ENZN 2023-12-26 269.2 2.8 -29.0 -42.6
ENZN 2023-12-22 284.6 2.9 -30.7 -42.2
ENZN 2023-12-21 292.3 3.0 -31.5 -42.0
ENZN 2023-12-20 284.6 2.9 -30.7 -42.2

ENZN Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 38.5%.
  • The 4 year cash and equivalents growth rate now stands at -36.33%.
  • Its 5 year net income to common stockholders growth rate is now at 57.46%.
ENZN's revenue has moved down $178,000 over the prior 33 months.

The table below shows ENZN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.029 -1.039 -2.852
2022-06-30 0.029 -1.397 -3.038
2022-03-31 0.32 -0.758 -2.819
2021-12-31 0.701 -0.501 -2.492
2021-09-30 0.706 -0.796 -2.638
2021-06-30 0.714 -0.794 -2.313

Enzon Pharmaceuticals (ENZN) Company Bio


Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.


ENZN Latest News Stream


Event/Time News Detail
Loading, please wait...

ENZN Latest Social Stream


Loading social stream, please wait...

View Full ENZN Social Stream

Latest ENZN News From Around the Web

Below are the latest news stories about ENZON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENZN as an investment opportunity.

7 Undervalued Biotech Stocks to Buy Before They Boom

Speculative investors should consider building a position in these undervalued biotech stocks before the market rebounds.

Josh Enomoto on InvestorPlace | November 30, 2022

Read More 'ENZN' Stories Here

ENZN Price Returns

1-mo -18.62%
3-mo -23.81%
6-mo -57.87%
1-year -68.63%
3-year -84.49%
5-year 63.27%
YTD -14.53%
2023 -62.06%
2022 -27.97%
2021 37.88%
2020 20.58%
2019 284.33%

Continue Researching ENZN

Here are a few links from around the web to help you further your research on Enzon Pharmaceuticals Inc's stock as an investment opportunity:

Enzon Pharmaceuticals Inc (ENZN) Stock Price | Nasdaq
Enzon Pharmaceuticals Inc (ENZN) Stock Quote, History and News - Yahoo Finance
Enzon Pharmaceuticals Inc (ENZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!